New York State Common Retirement Fund Sells 7,839 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New York State Common Retirement Fund lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 162,338 shares of the biopharmaceutical company’s stock after selling 7,839 shares during the period. New York State Common Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $133,598,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Sunbelt Securities Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $25,000. BerganKDV Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 444.4% in the 2nd quarter. BerganKDV Wealth Management LLC now owns 49 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 40 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1,933.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 61 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 58 shares during the last quarter. Milestone Investment Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $54,000. Finally, Grove Bank & Trust boosted its stake in shares of Regeneron Pharmaceuticals by 27.8% in the 3rd quarter. Grove Bank & Trust now owns 69 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 15 shares during the last quarter. 84.15% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now owns 6,382 shares of the company’s stock, valued at $6,062,900. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Christopher R. Fenimore sold 2,448 shares of the company’s stock in a transaction that occurred on Wednesday, December 27th. The stock was sold at an average price of $856.71, for a total transaction of $2,097,226.08. Following the transaction, the senior vice president now owns 14,372 shares of the company’s stock, valued at $12,312,636.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 2,707 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the transaction, the director now directly owns 6,382 shares in the company, valued at approximately $6,062,900. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,084 shares of company stock valued at $8,091,335. 8.83% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 9th. They issued a “hold” rating and a $800.00 price target on the stock. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Cantor Fitzgerald reissued a “neutral” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, January 9th. Piper Sandler boosted their price target on Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. Finally, Truist Financial reissued a “buy” rating and set a $1,045.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, December 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $925.52.

View Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock opened at $959.73 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $960.21. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.18 and a quick ratio of 4.47. The stock’s 50 day simple moving average is $877.95 and its two-hundred day simple moving average is $830.00. The company has a market cap of $104.56 billion, a PE ratio of 27.37, a price-to-earnings-growth ratio of 2.88 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.39 by $0.78. Regeneron Pharmaceuticals had a return on equity of 18.61% and a net margin of 30.47%. The business had revenue of $3.36 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the prior year, the business posted $9.98 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.95 earnings per share for the current year.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.